Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Cormorant Asset Management bought 251,600 additional shares of Rapport Therapeutics (NASDAQ:RAPP), raising its position to 3,192,521 shares valued at $94.82 million at quarter-end and increasing the stake by roughly $61.38 million; the holding now represents 6.54% of Cormorant’s 13F AUM and the position is the fund's fourth-largest. Rapport shares were $24.37 on Nov. 14, 2025 (market cap ~$1.49 billion) after recent positive phase 2a data and a Sept. 8 52-week high of $42.27; the company is clinical-stage with TTM net loss of ~$97.7 million, Q3 net loss of $26.9 million and cash of ~$513 million (runway into H2 2029). The trade signals institutional confidence following clinical progress but the stock remains binary and high-risk given lack of revenue and reliance on RAP-219 clinical outcomes.

Analysis

Market structure: Cormorant’s ~3.19M-share accumulation (position now ~$95M, 6.54% of its 13F AUM) tightens float and signals institutional appetite for RAP-219 after positive phase 2a data. Direct winners are Rapport (RAPP), CROs and early-stage CNS specialists; losers are short sellers and undifferentiated CNS small-caps that lack clinical readouts. Limited free float plus concentrated ownership increases price sensitivity to any buy/sell flow, supporting higher expected realized vol and bid-side resilience on positive news.

Risk assessment: Key tail risks are a failed phase 3 or unexpected safety signal that could halve market cap (>50% drawdown), or a dilutive secondary raise despite reported $513M runway to H2 2029 if timelines slip. Near-term (days-weeks) risks are headline-driven reprices; medium-term (3–12 months) risks include trial starts/financing; long-term outcome hinges on regulatory approval and reimbursement. Hidden dependencies include CRO enrollment timelines, partnering/licensing cadence, and Cormorant’s potential exit-trigger levels.

Trade implications: Favor asymmetric exposure: defined-risk option structures or small-sized equity buys. Volatility should remain elevated into next clinical milestones—use 9–18 month call spreads to capture upside while capping premium, or buy puts as tail protection. Relative plays: long RAPP vs short an undifferentiated biotech like BBIO (to hedge beta) because RAPP has clearer binary catalysts and a multi-year cash runway.

Contrarian angles: Consensus may overvalue phase 2a evidence—phase 3 failure rates for CNS drugs are materially higher; the market may be underpricing dilution risk if timelines slip. Cormorant’s buy could be momentum-following rather than deep fundamental conviction; that makes stop-loss discipline critical. Historical parallels (single-asset biotechs that doubled on phase2 then collapsed on phase3) argue for small, hedged positions and treating gains as realizable at predefined thresholds.

Key Decisions for Investors

• Establish a tactical long in RAPP equal to 1–3% of portfolio (size dependent on risk budget) using a 9–18 month call spread (buy $25–$35 call, sell $45–$55 call depending on available strikes) to limit premium and capture upside to a $40+ target; reassess after any phase 3 start or interim readout.
• If preferring equity, scale in on weakness: accumulate into $18–$20 (≈25% below current $24.37) with a hard stop-loss at 25% below entry and plan to take at least half profits if price >$40 or on a positive phase 3 top-line.
• Implement a hedged pair: go long RAPP (0.5–1% portfolio) and short BridgeBio (BBIO) at a notional ratio that neutralizes broad biotech beta (use historical 60–90 day beta to size) to isolate RELATIVE RAP-219 clinical upside vs sector risk.
• Buy 12–18 month puts on RAPP sized to cover 50–75% of the equity stake as tail insurance if you hold >1% position; alternatively, buy protective 12-month puts with strike ~30% OTM to insure against phase 3/regulatory failure while preserving upside.